Mirum Pharmaceuticals Price Target Raised to $160.00/Share From $155.00 by Cantor Fitzgerald

What happened

Cantor Fitzgerald raised its price target for Mirum Pharmaceuticals to $160.00 per share from $155.00 per share. The firm maintained its Overweight rating on the company, according to the supplied ratings-action report.

Confirmed

Global impact / market context

A higher price target signals that Cantor Fitzgerald now sees more potential value in Mirum shares than its prior target implied. The unchanged Overweight rating indicates the firm retained its positive view, but the report gives no reasons or estimates behind the change.

Analyst inference

This is an analyst opinion update, not a report of Mirum’s financial results or a company announcement. The target change alone does not establish a change in sales, costs, cash available, or business prospects, and the supplied context gives no share-price reaction.

Analyst inference

What to watch

1. Watch for further analyst updates that explain whether Cantor Fitzgerald’s higher target reflects changed assumptions about Mirum’s revenue, costs, or future cash generation. Analyst inference
2. Check whether Cantor Fitzgerald changes its Overweight rating in a later update; the supplied report says that rating was maintained alongside the higher target. Confirmed
3. Compare future company results and guidance with any assumptions disclosed in later research, since this brief gives no rationale for the target increase. Analyst inference

Evidence

• Original source link unavailable